

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

REC'D 3:1 MAR 2006  
 WIPO PCT

## PCT

### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

To:  
G.E. Ehrlich (1995) LTD.  
G. E. EHRLICH (1995) LTD.  
11 MENACHEM BEGIN STREET  
RAMAT GAN, ISRAEL 52 521

Applicant's or agent's file reference 30236		Date of mailing (day/month/year) <b>28 MAR 2006</b> <b>FOR FURTHER ACTION</b> See paragraph 2 below	
International application No. PCT/IL05/01022	International filing date (day/month/year) 25 September 2005 (25.09.2005)	Priority date (day/month/year) 17 November 2004 (17.11.2004)	
International Patent Classification (IPC) or both national classification and IPC IPC: C07K 14/00( 2006.01),14/75( 2006.01);A61K 38/16( 2006.01),38/36( 2006.01) USPC:			
Applicant VASCULAR BIOGENICS LTD.			

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

#### 2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Date of completion of this opinion 20 February 2006 (20.02.2006)	Authorized officer Ron Schwadron, Ph.D. <i>[Signature]</i> Telephone No. 571 272 1600
--	---	---

Form PCT/ISA/237 (cover sheet) (April 2005)

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/IL05/01022

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of:

- ☒ the international application in the language in which it was filed  
☐ a translation of the international application into \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

- ☐ a sequence listing  
☐ table(s) related to the sequence listing

b. format of material

- ☐ on paper  
☐ in electronic form

c. time of filing/furnishing

- ☐ contained in the international application as filed.  
☐ filed together with the international application in electronic form.  
☐ furnished subsequently to this Authority for the purposes of search.

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/IL05/01022

**Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)

Claims NONE YES

Claims 1-28 NO

Inventive step (IS)

Claims NONE YES

Claims 1-28 NO

Industrial applicability (IA)

Claims 1-28 YES

Claims NONE NO

**2. Citations and explanations:**

Please See Continuation Sheet

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/IL05/01022

**Supplemental Box**

In case the space in any of the preceding boxes is not sufficient.

**V. 2. Citations and Explanations:**

Claims 1-28 meet the criteria set out in PCT Article 33(4), and thus exude industrial applicability because the subject matter claimed can be made or used in industry.

Claims 1-28 lack novelty under PCT Article 33(2) as being anticipated by WO 02/053092.

WO 02/053092 discloses the methods of claim 1-5 (see claims 11-16) using human B2GPI (see page 25). The methods of claims 6-18 occur inherently in the methods of claims 1-5 of WO 02/053092 because both methods administer the same ingredients to the same patients. WO 02/053092 (claims 1-7) teaches the claimed article of manufacture wherein the intended use or label or insert carry no patentable weight